Through the power of large language models and generative AI, pharma and biotech companies are transforming medical information delivery by offering direct, trustworthy, and accurate answers to patients and healthcare providers, significantly reducing time and frustration.
Prices not likely to change upon release.
Senior editor Fran Pollaro chats with Sharlene Jenner, vice president of engagement strategy, Abelson Taylor about the transformative impact and ethical considerations of AI in the pharmaceutical industry, emphasizing its potential in data analysis and marketing, while also highlighting the pioneering work of AI companies in advancing drug discovery.
Deal comes amid collaboration on encapsulated cell therapies.
Investor claims agreement not suitable for shareholders.
Venture designed to streamline drug development and clinical trials.
Gallery showcases experience of living with generalized pustular psoriasis.
Pharmaceutical company expects deal to further augment capabilities.
Medication is the first of its kind approved for patients as young as 12.
Deborah Dunsire set to retire later this year.
Senior editor Fran Pollaro interviews Veeva's Paul Shawah about the dynamic future of field teams in biopharma. The chat highlights the transformative power of data and artificial intelligence (AI) in advancing precision medicine.
Drug expected to support children aged 4 and 5 with Duchenne muscular dystrophy.
Medications expected to improve blood sugar control in children 10 years and older.
Project intends to increase diverse representation in medical imagery.
Medicine created for patients with difficulty swallowing tablets.
Group to be fully integrated into Verix lab.
Initiative to support developing manufacturers launch new products.
Collaboration to focus on personalized medicine in the United Arab Emirates capital.
Pharma giant to absorb oral treatment specialist.
Biopharma aims to strengthen field engagement with healthcare professionals.
Company reportedly on schedule to make drug available in the second half of this year.
Medicine expected to be available immediately via prescription.
Assets include cardiology, otic infections, and pain management.
Research to focus on the treatment of atherosclerotic cardiovascular disease.
Forces pharma giant to hand over marketing communications with Meta.
